ABOUT ME

I am a substance use researcher in the Section on Tobacco, Alcohol, and Drug Use in the Department of Population Health at New York University Grossman School of Medicine. My research addresses three priority areas of high-risk polysubstance use (i.e., co-use of substances known to contribute to overdose, primarily opioids & stimulants): (1) measurement of polysubstance use, (2) understanding patterns and correlates of polysubstance use patterns, and (3) interventions targeted to polysubstance use populations. My work in these areas is focused on patterns of use and outcomes among vulnerable and underserved populations (e.g., justice-involved, rural). I am particularly interested in interventions addressing PTSD among individuals engaged in opioid-stimulant polysubstance use and expanding naloxone for unintentional polysubstance exposure.  I am currently supported by a K01 career development award to develop a novel assessment tool to measure polysubstance use among vulnerable populations.

Select publications

Renn, T., Griffin, B., Kumaravelu, V., Ventuneac, A., Santacatterina, M., & Bunting, A. M. (2024). Study protocol for a randomized controlled trial to adapt a posttraumatic stress disorder intervention of patients with opioid-stimulant polysubstance use receiving methadone maintenance treatment. BMC Psychiatry, 24(1), 1-10.

Bunting, A.M., Shearer, R., Linden-Carmichael, A.N., Williams, A.R., Comer, S.D., Cerdá, M., & Lorvick, J. (2023). Are you thinking what I’m thinking? Defining what we mean by “polysubstance use.” The American Journal of Drug and Alcohol Abuse, 1-7.

Bunting A.M., Krawczyk, N., Choo, T.H., Pavlicova, M., McNeely, J., Tofighi, B., Rotrosen, J., Nunes, E. and Lee, J.D. (2022). Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes. Journal of Substance Abuse Treatment, 143.